Alyeska Investment Group L.P. Makes New $632,000 Investment in BiomX Inc. (NYSEMKT:PHGE)

Alyeska Investment Group L.P. acquired a new stake in shares of BiomX Inc. (NYSEMKT:PHGE) in the 4th quarter, Holdings Channel.com reports. The fund acquired 865,400 shares of the company’s stock, valued at approximately $632,000.

Separately, Allostery Investments LP purchased a new position in BiomX during the fourth quarter valued at $470,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of BiomX in a research note on Friday, April 4th.

BiomX Trading Down 26.3 %

NYSEMKT:PHGE opened at $0.55 on Wednesday. The stock has a market cap of $13.62 million, a price-to-earnings ratio of -0.73 and a beta of 1.51. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average price is $0.58 and its 200-day moving average price is $0.68. BiomX Inc. has a 52 week low of $0.48 and a 52 week high of $4.90.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.